BostonGene AACR 2026 highlights the company’s strong presence at the upcoming oncology event. The company will present 13 abstracts at the American Association for Cancer Research Annual Meeting 2026. The event will take place from April 17 to April 22 in San Diego, California. Meanwhile, BostonGene will exhibit its solutions at booth #4613.
BostonGene will demonstrate its AI foundation model for tumor and immune biology. This model supports drug development across the entire lifecycle. Moreover, it helps biopharma companies improve discovery and clinical outcomes. The platform integrates genomic, transcriptomic, and spatial data insights. As a result, it enables faster and more reliable drug development processes. Additionally, it reduces risks in pharmaceutical pipelines.
Key research includes tools like ReadyScore and Lymphly. These tools enhance patient stratification and target identification. Furthermore, RNA-based diffusion models predict drug-induced tissue changes. BostonGene will also present AI-based image correction technology. This technology improves clinical trial data accuracy. Consequently, it ensures analysis focuses on true biological signals. In collaboration with leading institutions, BostonGene explores multiomic profiling. This approach identifies biomarkers and resistance pathways. Notably, traditional methods often miss these insights.
Key Research Highlights at AACR 2026
BostonGene will present findings from multiple clinical and research studies. One oral session will evaluate zanidatamab in HER2-positive breast cancer. The study shows promising efficacy and manageable safety outcomes.
Researchers used whole exome sequencing and RNA sequencing platforms. These methods identified markers of treatment response. Therefore, the findings support targeted therapy approaches.
Poster presentations will cover diverse oncology topics. For instance, cfRNA profiling reveals tumor-specific gene expression patterns. This method enables non-invasive cancer monitoring and diagnosis.
Another study highlights AURKA inhibition in inflammatory breast cancer. Researchers identified potential synthetic lethality with SMARCA4. Thus, it opens new therapeutic opportunities.
BostonGene will also present a scoring framework for multiple myeloma therapies. This framework predicts treatment response using tumor and microenvironment data.
Additionally, RNA-driven diffusion models will demonstrate tissue prediction capabilities. These models simulate drug effects on tissue structure. Consequently, they improve early-stage drug evaluation.
The company will also showcase Lymphly for lymphoma classification. This framework identifies molecular relationships across lymphoma subtypes.
Further studies explore kidney cancers and metabolomic biomarkers. These findings support improved patient stratification and treatment planning.
BostonGene will also introduce an AI-powered image correction tool. This tool standardizes histological data across different imaging systems.
Moreover, the BEGIN study highlights integrated DNA and RNA profiling. The study shows 93% of patients had actionable insights. Therefore, it emphasizes the value of comprehensive genomic testing.
Finally, BostonGene will present immunotherapy research in liver cancer. The study shows improved immune response using combination therapies.
Overall, BostonGene AACR 2026 demonstrates the company’s leadership in AI-driven precision oncology. The presentations highlight innovation in biomarker discovery, clinical trials, and drug development.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
